Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26

Introduction

Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease progression and long-term hepatic outcomes has remained uncertain.

This large, multicohort study addresses that gap by asking a simple but important question:

Does hypertension independently worsen outcomes and fibrosis progression in MASLD?

What the investigators did:

The authors analysed three large, complementary cohorts:

A population-based cohort to assess long-term clinical outcomes (death, cardiovascular events, liver-related events).

A noninvasive elastography cohort to evaluate liver stiffness progression over time.

A paired liver biopsy cohort to directly measure histologic fibrosis progression.

By combining population data, noninvasive markers, and histology, the study provides a uniquely robust picture of disease evolution.

Key findings clinicians should understand

1) Hypertension independently worsens long-term outcomes

Patients with MASLD and hypertension experienced more adverse clinical events over time—not only cardiovascular events, but also liver-related complications and mortality.

2) Hypertension accelerates liver disease progression

Across two independent measures of disease activity:

Liver stiffness increased faster, and

Fibrosis progressed more frequently

in patients with hypertension compared with those without.

3) This is not just association—it’s consistent across methods

The relationship between hypertension and MASLD progression was seen:

in population-level data,

with noninvasive fibrosis assessment, and

on paired histologic evaluation.

This consistency strongly supports a true biological link, not just confounding.

Why this matters clinically

Hypertension is modifiable

Unlike many genetic or metabolic drivers, blood pressure is treatable—making it a practical intervention point.

MASLD care must be multidisciplinary

These findings emphasize that optimal MASLD management requires:

hepatology,

cardiology,

and primary care alignment.

Risk stratification should change

Patients with MASLD and hypertension represent a higher-risk subgroup who may benefit from:

closer fibrosis monitoring,

earlier use of noninvasive tools (e.g., elastography), and

more aggressive cardiometabolic risk control.

Pathophysiologic perspective:

Hypertension may contribute to liver injury through:

endothelial dysfunction,

altered hepatic microcirculation,

systemic inflammation, and

shared metabolic pathways with insulin resistance.

These mechanisms provide biologic plausibility for the observed acceleration of fibrosis.

Bottom-line takeaway from GastroAGI

Hypertension is not just a cardiovascular comorbidity in MASLD—it is a key, modifiable driver of liver disease progression and adverse outcomes. Blood pressure control should be a core component of MASLD management.

One-line GastroAGI takeaway

In MASLD, controlling blood pressure may help protect the liver as much as the heart.